Director, Evidence Generation & Strategy
bioMerieux SA
Aumenta le possibilità di ricevere una risposta da questo datore di lavoro
Il tuo curriculum e una lettera di presentazione personalizzati, che corrispondono esattamente a ciò che sta cercando.
Vantaggi offerti da questo lavoro
Descrizione del lavoro
bioMérieux SA in Salt Lake City, UT is seeking a Director of Evidence Generation Planning & Methodology to lead scientific strategy and methodological excellence across our portfolio. You will translate clinical and epidemiological needs into integrated evidence plans and partner with Medical Affairs to address meaningful healthcare decisions.
You will build and guide a high‑performing team, set priorities, allocate resources, and foster a culture of rigor, collaboration, and continuous
Competenze
- Proven ability to lead strategic scientific directions and evidence priorities.
- Experience building and guiding high‑performing scientific teams.
- Track record of advancing evidence generation across portfolios.
- Strong publication and scientific communication expertise.
Mansioni
- Shape scientific direction, priorities, and methodological standards within Medical Evidence Generation.
- Lead and develop a high‑performing team of scientific and methodological experts.
- Provide governance input on study design and methodological quality.
- Guide integrated evidence generation planning across disease areas and portfolios.
- Foster cross‑functional partnerships with Medical Affairs, Biostatistics, Regulatory, and Market Access.
Conoscenze
Formazione
Descrizione del lavoro
bioMérieux SA in Salt Lake City, UT is seeking a Director of Evidence Generation Planning & Methodology to lead scientific strategy and methodological excellence across our portfolio. You will translate clinical and epidemiological needs into integrated evidence plans and partner with Medical Affairs to address meaningful healthcare decisions.
You will build and guide a high‑performing team, set priorities, allocate resources, and foster a culture of rigor, collaboration, and continuous
'/%3e%3cpath%20d='M101.744%2012.4726L102.894%2016.1947L99.0021%2013.2201L101.744%2012.4726ZM105.3%208.40937H100.488L99.0026%203.59473L97.5116%208.41047L92.7%208.40385L96.5965%2011.3834L95.1055%2016.1942L99.0021%2013.2196L101.408%2011.3834L105.3%208.40992V8.40937Z'%20fill='white'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear_5593_1381'%20x1='90'%20y1='9.44471'%20x2='99'%20y2='9.44471'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%2300AD70'/%3e%3cstop%20offset='0.998594'%20stop-color='%2300B67A'/%3e%3cstop%20offset='1'%20stop-color='%23DCDCE6'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e){kind=small}
